The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

Disclosed herein are devices that can be used to detect neutralizing antibodies against multiple pathogens in a quick and accurate manner. An example device includes a substrate; a non-fouling layer; a plurality of pathogen regions, each pathogen region including a different pathogen; and at least one detection region, the detection region including a detection agent that is capable of specifically binding each pathogen and an excipient. In addition, an example method includes contacting a biological sample with a device, and detecting the presence of a neutralizing antibody in the biological sample for each pathogen, wherein the presence of the neutralizing antibody is detected by inhibiting the binding of the detection agent to each pathogen.

Arrays comprising probes comprising probes from more than one influenza strain or subtype are provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.

A lateral flow assay device includes a test strip that is configured to receive a sample fluid and detect a presence of antibodies to one or more of a plurality of proteins of the target pathogen. The lateral flow assay device includes a conjugate pad and a membrane. The conjugate pad contains a plurality of the proteins of the target pathogen, each conjugated with a label. If the sample fluid contains antibodies that are specific to the target pathogen through any of the target pathogen's proteins, a binding takes place between those antibodies and the corresponding tagged protein. The membrane may include a plurality of test lines. Each test line may contain the immobilized binding reagent to one antibody class, resulting in the concentration of all the molecules of that antibody class on the test line.

The present invention relates to a method for predicting and monitoring the severity of COVID-19 disease following infection of a subject with the SARS-CoV-2 virus. It also relates to a method for the treatment of a subject with COVID-19 disease. It also relates to kits for use in the methods of the invention.

This technology relates in part to optical methods for analyzing particles, including nanoparticles, thereby determining their presence, identity, origin, size and/or number in a sample of interest.

The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

A biochemical detection device is revealed. The biochemical detection device includes a cap and a base arranged at two ends of a test tube correspondingly and a driving member disposed on the base. A sample-mounting slot and a test-paper-mounting slot separated from each other are formed in the test tube. After sampling, a sample obtained is placed into the sample-mounting slot and mixed with an extraction solution therein. A thin-film on the sample-mounting slot is penetrated by the driving member to allow the extraction solution mixed with the sample flowing into a cavity of the test tube to react with a test strip in the test-paper-mounting slot. The test cost is reduced and the detection efficiency is improved due to simple structure and easy operation. Moreover, the sample and the extraction solution are sealed in the test tube to prevent environmental pollution caused by spread of viruses.

The method of the present disclosure comprises the following steps: providing a SERS-active substrate and a Raman spectra virus database; applying a virus sample onto the SERS-active substrate; applying an incident light by a Raman spectrometer onto the SERS-active substrate to generate a Raman spectrum of the virus sample; and comparing the Raman spectrum of the virus sample with a Raman spectra virus database to identify the species of the virus sample. Herein, the SERS-active substrate comprises: a support; a dielectric layer disposed on the support, wherein a plurality of cavities are formed on a surface of the dielectric layer; and a plurality of noble metal clusters formed in the plurality of cavities.

The current invention provides a multiplex method for screening bovine samples for antibodies against several important pathogens. These pathogens include Bovine Viral Diarrhoea Virus (BVDV), Bovine Herpesvirus-1 (BoHV-1), Mycobacterium paratuberculosis (MAP), Leptospira species, Neospora caninum and Fasciola hepatica. This multiplex screening is enabled by substrates with immobilized pathogen antigens and offer multiple advantages for the routine testing of farm animals.